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HL-A  antigens  are gene products  of  the  major  histocompatibility locus  in  man 
(i). These cell surface antigens are the human counterparts of the H-2  (2,3),  AgB 
(4),  CHL-A  (5),  and  DL-A  (6)  antigen  systems  in  mice,  rats,  chimpanzees,  and 
dogs,  respectively, In  the  past  few  years  there  have  been  considerable efforts  to 
elucidate  the  genetic  and  chemical  characteristics  of  the  various  HL-A  antigens 
largely  because  of  their  crucial  roles  in  transplantation  immunity.  Although  the 
singular capacity of this system to regulate the survival of tissue grafts has recently 
been questioned (7),  there is no doubt that the HL-A system is a  controlling factor 
of the allograft rejection process. 
Aside  from  the  importance  of  histocompatibility antigens  in  transplantation, 
interest in the biology of this system stems from studies which suggest that there is 
a  relationship between  particular histocompatibility antigens  and  the  immune  re- 
sponse to certain antigens as well as the capacity to resist disease (8). Thus,  inbred 
strains of  mice  differing only at  the H-2  locus vary markedly in  the  incidence of 
spontaneous tumors and in their susceptibility to tumor induction by various agents 
(9,  10). The counterpart of this observation in human pathology may be the statistical 
correlation which  prevails between certain  histocompatibility antigens  and  several 
forms of neoplastic and autoimmune diseases (10). 
Since HL-A antigens are located on the surfaces of cells, they provide excel- 
lent markers with which  to study various membrane properties and functions 
such  as cytoarchitecture, permeability, metabolism,  and cell recognition. Hu- 
man lymphoid cells are particularly useful for these studies because they can be 
maintained in continuous culture and their growth can be synchronized. 
In this project we have investigated HL-A antigenic expression on  the sur- 
faces  of  synchronized  human  lymphoid cells during  different phases  of  their 
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growth  cycle  as  judged  by  sensitivity  to  lysis  in  the  complement-dependent 
cytotoxic test, ability to activate the complement effector system, and quantita- 
tive absorption studies of HL-A  alloantisera. 
Malerials and Methods 
lhtman Lymphoid Cdl Line.--The WI-L2 cell line which was originally derived from splenic 
lymphocytes of a patient with hereditary spherocytic anemia (11)  was used in these experi- 
ments. The HL-A phenotype is HL-A1,2,5, Te (W 17) as determined by direct cytotoxic test 
and  by absorption typing  (12).  Suspension cultures were grown and propagated  in Eagle's 
minimal essential medium (MEM; 1 Autopow, Flow Laboratories, Inc., Rockville, Md.), sup- 
plemented with glutamine, nonessential amino acids, pyruvate, 10c?} fetal calf serum, penicillin, 
streptomycin, and Fungizone as described by Lerner and Hodge (13).  Cell concentration and 
viability were determined by trypan blue exclusion using a hemacytometer. 
Synchronizalion of Cells.--WI-L2 cells were synchronized by following the procedure de- 
scribed by  Lerner and Hodge (13). Briefly, cultures were started at concentrations of 4 X  105 
cells/ml. The extent of DNA synthesis and cell viability were the criteria by which cell life 
cycles were followed.  When the rate of DNA synthesis was approximately 2% of the maximum 
(Go  or stationary phase of cell growth), the resting cells were harvested and resuspended in 
fresh, prewarmed (37°C)  medium and the course of DNA synthesis ascertained to determine 
G1 and S phase, respectively. 
HL-A  Alloantisera.--The  alloantisera  Lewandowski  2 60-0-05-21-01  (anti-HL-A1), 
Gillespie  2-50-9-03-21-01  (anti-HL-A1),  Pinquette  2-50-6-09-01  (anti-HL-A2),  Stockenberg 
1-04-0-07-08-01  (anti-HL-A2), McMullen 2-65-0-03-30-01  (anti-HL-A5), Peterson 1-08-9-01- 
08-01  (anti-HL-A12), and Viktor  1-01-9-07-17-04  (anti-HL-A5)  which were utilized in  this 
study were obtained from the serum bank at the National Institute of Allergy and Infectious 
Diseases and from the laboratories of Doctors R. Ceppellini, R. Payne, and P. I. Terasaki. All 
of the sera had been frozen and thawed several times. 
Rabbit  Anti-Human  Lymphocyte Sera.  Sera  were  harvested from  New  Zealand  rabbits 
immunized with washed cultured human lymphoid cells according to the method of Levey and 
Medawar  (14).  The sera had a  titer of 1:16,000 against human lymphoid cells in the micro- 
lymphocytotoxic  test.  Before  testing with cultured  human lymphoid  cells,  the  serum was 
inactivated by heating for 30 rain at 56°C  to destroy the natural rabbit antibodies directed 
against antigens present on human lymphoid cells (15). 
Complement.--Rabbit  complement was  a  pool  of  nine  rabbits' sera  selected  after  their 
individual bleedlngs proved nontoxic in the eytotoxic assay with peripheral lymphocytes from 
four subjects of different ABO groups. A pool of fresh sera derived from five healthy donors 
with no previous history of pregnancy or blood transfusion served as the source of human 
complement. The complement pools were stored at  -70°C  in small samples and used only 
once after thawing. Purified human complement components C1, C2, C3, C4, C5, C6, C7, C8, 
and C9 were isolated from human serum by published methods (16-18) 2' a. They were utilized 
for molecular hemolytic titrations (17-19). Preparations of C6, C7, and C8 were trace labeled 
with l~r'I by the chloranfine-T method (20) without loss of activity and used for quantitative 
cell-binding studies. The specific radioactivity was, respectively, 8.1  X  10 a, 0.4  X  10 a, and 
1 X  106 cpm//~g of C6, C7, and C8,  values which correspond to 0.92,  1.02, and 1.1 p.Ci//zg. 
Cytotoxic Assay.~The  slightly modified eosin method according to Mittal et al.  (21)  was 
1 Abbreviations used in this paper: ADs0,50c{ absorption dosage; MEM,  minimal essential 
medium. 
2 Haxby, J., and H. J. Mtiller-Eberhard. Manuscript in preparation. 
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used both with cultured human lymphoid cells (12) and with human peripheral lymphocytes. 4 
The reaction mixtures consisted of 1/tl of target cell suspension (2000 cells), 2 #1 of antisera, 
and 3/zl of complement. When cultured human lymphoid cells were the target cells,  human 
complement or a  mixture of  i  vol of rabbit complement and 3  vol of human complement 
(hereafter abbreviated as rabbit complement) were used as indicated below. When peripheral 
human lymphocytes were the target cells, the source of complement was undiluted fresh rabbit 
serum. 
Quantitation  of Activation  of the Complement System.--At  various  times  in  the growth 
of WI-L2 cells,  samples of 5  X  105 cells were withdrawn, washed three times in phosphate- 
buffered solution (0.005  M  sodium phosphate buffer, 0.15 M  NaC1,  pH 7.1),  and mixed with 
20 #I of antisera which had been previously heated at 56°C for 30 rain. After 10 rain of incuba- 
tion at 37°C, 40 #I of human complement was added and incubation continued for 60 min. 
Then the cells were sedimented by centrifugation at 13,000 g for 5 rain in a Beckman microfuge 
(Beckman  Instruments,  Inc.,  Fullerton,  Calif.)  and  the supernatant was analyzed for re- 
sidual C3,  C4, and C8 complement components by specific stoichiometric titrations with the 
human complement intermediate complexes EACI, 4, 2, EACI, and EACI, 4,  2, 3,  5,  6,  7, 
respectively (17,  19).  The results were expressed as the  percent  of  the  number of  effective 
molecules remaining in serum samples similarly incubated with cells and heated normal serum 
in place of antibody. 
Quantitation of Cell-Bound Radiolabeled C6,  C7,  and  CS.--Binding  of  complement com- 
ponents was studied exactly as was activation of complement components except that radio- 
labeled C6,  C7, and C8 were incorporated into the human serum complement source.  After 
completion of incubation, cells were washed four  times and analyzed for radioactivity in a 
well-type scintillation counter. Nonspecific binding of complement components was determined 
from reaction mixtures with heat-inactivated normal human serum in place of specific antisera. 
Specific  binding was obtained by subtracting the values for nonspeeific uptake from the total 
bound radioactivity. Nonspecific cellular binding of C6, C7, and C8 averaged 0.3-1.07% of the 
total radioactivity offered to  the cells.  Molecular weights of  125,000,  125,000,  and  150,000 
were used to calculate the number of bound C6, C7, and C8 molcules. In calculating these 
values, only the bound radiolabeled molecules were considered, since the concentration of un- 
labeled C6, C7, and C8 in the complement source was not known. 
Microabsorption Teehnique.--Quantitative  microabsorption test was performed as previously 
described (22). Briefly, 5#1 of HL-A alloantisera at  a  dilution corresponding to  1  cytotoxic 
unit was incubated in tubes with 5 #1 of varying concentrations of the cell suspension. 1 cyto- 
toxic unit is equal to twice the least amount of antiserum required to lyse 95% of the selected 
target cells. The  material was mixed at 10-min intervals for a total incubation period of 60 rain 
at room temperature. After incubation, the tubes were centrifuged for 5 rain at 13,000 g  in a 
Beckman microfuge. The supernatant fluid was transferred to fresh tubes and frozen at -20°C 
until it was tested for residual lymphocytotoxic activity against selected target cells. The 50% 
absorption dosage (AD~0) (the number of cells required to reduce by 5(?% the cytotoxicity  of 
a selected alloantiserum) was used as the parameter for comparison of results from the various 
quantitative absorptions. 
Determination of Cell Volume.--To  compare  the  respective  volumes  of  cells  in  phases 
of  the growth  cycle, a  known  number of WI-L2 cells were placed in cylindrical glass tubes 
(0.2  X  5 cm) and centrifuged at 450 g for 10 min at 4°C (23). The ratio of the respective cell 
volumes was considered equal to the height ratio of the packed cells. 
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RESULTS 
Relationship between the Stage of the Ceil Growth Cycle and the Susceptibility of 
WI-L2 Cells to Lysis in the Lymphocytotoxic Tests.--To investigate the relation- 
ship among phases of the growth cycles of WI-L2 cells and sensitivity to lysis 
mediated by anti-HL-A alloantibodies and complement, cells from log phase, 
Go, G1, and S phase cultures were tested with anti-HL-A1, 2, and 5 alloantisera 
and with rabbit serum as the complement source.  Cells in different phases of 
their growth elicited concordant  titers with the anti-HL-A alloantisera tested 
(Fig.  1).  Similar results were obtained with cells from cultures in late resting 
phase (cell concentration of the culture 2.8 X  10  ~  cells/ml). 
Rabbit serum is known to contribute natural  antibodies as well as comple- 
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FIG. 1. Relationship between phases of the growth cycle and susceptibility to lysis of cul- 
tured human lymphoid ceils WI-L2 by HL-A alloantisera and complement. The source of 
complement is a  mixture of fresh rabbit  and human  sera. Alloantiserum Pinquette  (anti- 
HL-A2) in panel A; alloantiserum Victor (anti-HL-AS) in panel B; alloantiserum Gillespie 
(anti-HL-A1) in panel C.  •  O, log phase; A--A,  resting phase; O--O,  Gz phase; 
&----A, S phase. 
ment components to the lymphocytotoxic reaction  (15).  In order to eliminate 
the possibility that cell cycle variability in  the cell  surface expression of the 
antigenic determinants against which the rabbit natural antibodies are directed 
might obscure a change in the expression of HL-A antigens, the cytotoxic test 
was performed with human complement which is not known to contain natural 
antibodies.  Although  the  titer  of HL-A  alloantisera  was  lower  when  human 
complement replaced rabbit complement, the sensitivity of the cell membrane 
to the lyric action of anti-HL-A and human complement did not vary signifi- 
cantly during the cell cycle (Fig. 2). 
Activation  of the Complement System during the Cell Cycle by HL-A Antigens 
and HL-A Alloantisera.--Complement  activation was appraised by measuring 
the amount of the third, fourth, and eighth complement components remaining 
after incubation of human serum (40/zl), as the complement source, with HL-A 
alloantisera  (20/~l)  and WI-L2 cultured  lymphoid cells (5  X  10 a)  at various FERRONE,  COOPER,  PELLEGRINO,  AND  REISFELD  59 
times in the growth cycle. The ratio between cells,  antibody, and complement 
employed in these studies was chosen on the basis of preliminary experiments 
which indicated that fewer target cells produced little complement consump- 
tion.  With  larger numbers  of target  cells  marked  consumption  of the  early 
reacting complement components occurred in the absence of HL-A alloantisera. 
This "nonspecific" activation of the complement system could not be reduced 
by extensive absorption of the human complement with large numbers of cul- 
tured human lymphoid cells at 0°C; furthermore, it occurred with cells  at all 
phases of the cell cycle. 
The complement system was activated to a comparable extent at each phase 
of the growth cycle on addition of anti-lymphocyte serum to cells. Similar results 
were obtained throughout the cell cycle with each of the HL-A antisera tested. 
Fig. 3 shows representative results for the G1 and S phases of the growth cycle. 
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FIG. 2. Relationship between phases of the growth cycle and the susceptibility to lysis of 
cultured human lymphoid cells WI-L2 by HL-A alloantisera and human complement. Allo- 
antiserum Pinquette (anti-HL-A2) in panel A; alloantiserum Victor (anti-HL-A5) in panel B. 
Anti-HL-A1 alloantisera were not cytotoxic with human complement. 0----0, log phase; 
A----A, resting phase; ©--O,  Gz phase; A  A, S phase. 
There were, however, differences between the antisera in ability to activate the 
complement system. The consumption of C4 was  significantly greater in  the 
rabbit anti-human lymphocyte serum and anti-HL-A1 alloantiserum than with 
anti-HL-A2 and anti-HL-A5. The pattern of consumption of complement com- 
ponents observed with anti-lymphocyte serum and anti-HL-A1 is characteristic 
of that observed on activation of the classical complement pathway. The pat- 
tern of component consumption observed with anti-HL-A2 and anti-HL-A5 is 
somewhat different; it may well be that these antisera activate the alternate as 
well as the classical pathways. 
Binding of Complement Components by Sensitized Cultured Lymphoid Cells.- 
In order to determine if the ability of WI-L2 cells to bind late reacting comple- 
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containing radiolabeled C6,  C7, or C8 was added to cells which had been sen- 
sitized with anti-lymphocyte serum or HL-A alloantisera after varying periods 
of growth. The ability of each of the antisera to induce C6, C7, and C8 binding 
did not vary significantly during the cycle (Fig. 4). The various antisera differed 
in  the extent of binding with anti-lymphocyte serum inducing  approximately 
10-fold  greater  binding  of  C6,  C7,  or  C8  than  anti-HL-A2  or  anti-HL-A5. 
Anti-HL-A2  and  anti-HL-A5  triggered  comparable  binding  of  late  reacting 
complement components,  approximately  threefold greater  than  the  baseline. 
Throughout the cell cycle, the binding of labeled complement components by 
ceils sensitized with HL-A1 alloantisera did not exceed background values. 
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Fzo.  3.  Consumption  of  complement  component  in  serum  exposed  to  cultured  human 
lymphoid cells WI-L2,  sensitized with rabbit  anti-human lymphocyte serum or with  HL-A 
al]oantisera. The patterns obtained in the G1 and S phase are shown; similar patterns of com- 
plement component consumption were observed with cells in either log or resting phase. 
Quantitative Absorption  Experiments with A nti-HL-A A lloantisera.--In order 
to gain additionat quantitative data about the cell surface expression of HL-A 
antigens during the cell cycle, the absorbing capacities of cells at different phases 
of the cell cycle for anti-HL-A1, 2, and 5 alloantisera were investigated. Cells in 
S phase displayed the greatest absorbing capacity, whereas cells in the G1 phase 
had a slightly higher absorbing capacity than Go cells (Table I).  The specificity 
of the absorption was illustrated by the finding that in all phases of the cell cycle 
which  were  analyzed  more  than  50,000  cells/#[  were  necessary  to  absorb 
anti-HL-A12  alloantisera which  were directed against  determinants not pre- 
sent on WI-L2  cells.  ADa0 value for HL-A2 specificity was significantly lower FERRONE,  COOPER~  PELLEGRINO,  AND  RE,  ISFELD  61 
than  those for  HL-A1  and  HL-AS, suggesting that  a  different number  of an- 
tigenic determinants may be  available to react with various alloantibodies. 
The volume of the cells at different stages of the cell cycle was determined to 
ascertain whether variations with accompanying changes in surface area could 
account for  the differences in AD~0 values observed between S  and G~ phases. 
The volume of cells in G, phase was 1.4-fold smaller than that of cells in S phase, 
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FIG.  4.  Binding  of  ]2~I-radiolabeled  late complement  components  by  cultured human 
lymphoid cells WI-L2 sensitized with either rabbit anti-human lymphocyte serum (©----O), 
anti-HL-A2 alloanfiserum  (A  z~), anti-HL-A5 aUoantiserum  (V  V), or anti-HL-A1 
alloantiserum (Ul----[~) and incubated with serum cotttaining  [1~5I]C6, [12aI]CT, or [125IIC8. 
The stippled area represents binding observed in the absence of antiserum. Samples taken at 
38, 65, 2, and 18 h represent log, resting, G1, and S phases, respectively. 
TABLE  I 
Absorbing Capacity of Cultured Human Lymphoid Cells WI-L2 
in Different Phases of the Growth Cycle 
Phase of cell  Time after release  ADso 
cycle  from Go  HL-A1  HL-A2  HL-A5  HL-A12 
Go  --  1750  900  2000  > 50,000 
G1  2  1600  850  2000  > 50,000 
S  12  700  350  900  > 50,000 
which  is consistent with  the  mentioned differences in ADs0 values,  especially 
since the cells in S  phase have considerably more rnicrovilli and thus more ir- 
regular and larger areas than cells in G1 phase. 
DISCUSSION 
The  results  of  this  study  indicate  that  there  is  no  significant  variation 
throughout the cell growth cycle in (a) the sensitivity of cultured WI-L2 lymph- 62  HL-A  ANTIGENS  IN  SYNCHRONIZED  LYMPHOID  CELLS 
oid cells to HL-A antibody-mediated lysis in the cytotoxic test, (b) the extent of 
activation of the complement system, (c) the degree to which labeled complement 
components bind  to cells,  and  (d)  the  ability of  these  cells  to  absorb HL-A 
alloantibodies.  In addition,  there was no significant difference in  the  titers of 
cytotoxic HL-A alloantisera tested with cultured cells at various phases of their 
cell growth cycle when a mixture of rabbit and human sera was employed as the 
cytolytic reagent. Since rabbit serum is known to contribute natural antibodies 
directed against determinants present on lymphoid cells, as well as complement 
components  (15),  this  finding  indicates  that  there  is  no  detectable  change 
throughout the growth cycle in either those antigens against which the natural 
rabbit antibodies are directed or in the HL-A determinants as far as their avail- 
ability to combine with antibodies and to activate complement is concerned. 
It has recently become clear that there are two pathways of activation of the 
terminal portion of the complement sequence (24  26). One mechanism of activa- 
tion,  termed the classical pathway', involves C1,  C4,  and  C2  whereas  an un- 
known number of serum factors  are involved in  the  alternate pathway; both 
pathways converge at the step where C3 becomes involved. Activation of the 
classical pathway is reflected by the marked consumption of the early compo- 
nents C1,  C4,  and C2, while little depletion of these components is seen upon 
activation of the alternate pathway (26). a 
The reaction patterns of rabbit anti-human lymphocyte sera and anti-HL-A1 
alloantisera used in the present study were typically those of complement con> 
ponent consumption after activation of the classical pathway. The anti-HL-A2 
and anti-HL-A5 antisera which were examined appeared to activate both path- 
ways. Although comparison of the extents of activation of complement by the 
various  antisera  is  difficult  because  different  mechanisms  of  activation  were 
apparently involved, all antisera appeared to elicit very similar levels of C3 and 
C8 consumption. The complement activation studies thus did not correlate well 
with the results of cytotoxic assays and of binding studies involving C6, C7, and 
C8 which indicated that HL-A2 and HL-A5 alloantisera were more potent than 
anti-HL-A1 alloantisera. Killing of target cells in the cvtotoxic test also failed to 
correlate with  the extent to which  the complement sequence was activated in 
previous studies of murine Moloney virus-induced  tumor cells sensitized with 
anti-Moloney virus antibody (27). Although sensitivity to complement-depend- 
ent lymphocytotoxicity during the cell cycle varied greatly in these studies, with 
the greatest killing of target cells occurring in the G1 phase, the extent of activa- 
tion of the complement system by the sensitized cells was essentially constant 
throughout the cell growth cycle. 
These data emphasize the complexity of the cytotoxic reaction, which is the 
final result of a series of interactions among antigenic determinants,  antibody, 
'~ Cooper, N. R. In Contemporary Topics in  MolecularlmmunoIogy. R.  A. Reisfeld and 
W. Mandy, editors. Plenum Publishing Corporation, New York. In press. FERRONE~  COOPER,  PELLEGRINO,  AND  REIS[FELD  63 
complement components, and the cell membrane. These variables influence the 
ultimate result of the reaction at different levels. The contribution of antigenic 
determinants is controlled by their density and distribution; if the fluid mosaic 
model of membrane structure recently proposed by Singer and Nicolson (28) 
proves to be correct, the diffusion of antigens within the cell membrane may 
cause additional variability. On the other hand, the reactivity of antibodies is 
determined by their affinity for antigen, by their ability to activate the comple- 
ment sequence, and probably by their concentration in the reaction mixture. It 
has already been emphasized that the requirement of complement varies among 
HL-A specificities since false negative reactions (CYNAP, i.e. cytotoxic nega- 
tive, absorption positive) occur most frequently with the HL-A specificity 4b 
(29). When rabbit serum is the source of complement, the influence of natural 
rabbit  antibodies directed against determinants present on human lymphoid 
cells  also  has  to  be  considered;  these  antibodies  not  only possess  different 
specificity and titer, but the determinants against which they are directed are 
expressed in variable amounts  6 on human lymphocytes from different subjects, 
and spatial relationships between these determinants and HL-A antigens may 
also influence cytotoxicity. The pathway of complement activated by the im- 
mune reaction may well determine the outcome of the cytolytic reaction. Studies 
with several types of cells indicate that the alternate pathway has poor cytolytic 
potential.  ~ Thus, an antigen-antibody complex on the cell surface which acti- 
vates  only the  alternate  pathway might well  be  noncytotoxic. In  order  to 
achieve  cytolysis,  complement  activation  must  be  sustained  and  proceed 
through the reaction of the ninth component; furthermore, the terminal steps, 
from C5 through C9, must occur on the surface of the target cell. Failure of any 
components to react for any reason or absence of a binding site for a late compo- 
nent preclude lysis. 
In the course of this study, it was observed that early reacting complement 
components were reduced in human complement after incubation with cultured 
WI-L2  cells  in  the  absence  of HL-A  antibodies.  This  type of  activation is 
analogous  to  that  induced by immune complexes.  While natural  antibodies 
directed against constituents of the cell  membrane of cultured cells  (30, 31) 
might be responsible for complement activation, we were unable to diminish the 
consumption of early reacting components significantly by extensive absorption 
of the human complement source with cultured lymphoid cells. Alternatively, it 
is possible that the membranes of lymphoid cells perpetuated in culture have 
characteristics  which  trigger  activation  of  complement.  In  fact,  peripheral 
lymphocytes do not activate the complement sequence when incubated with 
human complement in the absence of HL-A antibodies,  s 
6 Mittal, K.K.,  S.  Ferrone,  R.  A. Reisfeld, M.  R.  Mickey,  M.  A. Pellegrino, and P.  I. 
Terasaki.  Tissue Antigens. In press. 
7 G~itze, 0., and H. J. Mfiller-Eberhard. Unpublished observations. 
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The  cell  surface  expression  of histocompatibility  antigens  during  the  cell 
cycle has  been  investigated  in  murine  tumor  cells  (32)  and  in  human  cells 
derived from Burkitt lymphoma (33) : results different from those reached in this 
experiment have been obtained. In these studies with malignant cells,  the  cell 
surface expression of histocompatibility antigens varies during  the cell cycle, 
being maximal in  G1 phase on both human  and murine tumor cells.  It seems 
worthwhile to emphasize that results comparable to these were obtained also in 
this  laboratory when  some  techniques  employed in  the  present  study were 
utilized to investigate the cell surface expression of H-2  antigens  at different 
stages  of growth of murine  tumor cells? This observation underlines the real 
discrepancy of the results obtained with malignant murine and human cells vs. 
those found in  the present study with cultured human  cells (WI-L2) derived 
from a donor free of malignancy. The different results obtained with WI-L2 cells 
as compared with those found with other cultured lymphoid cells studied may 
indeed reflect the  different sources of the cells used.  Thus,  tumor cells were 
utilized  exclusively in  those  studies  where  histocompatibility  antigens  were 
preferentially expressed in G~ phase, while in the present investigation indicat- 
ing no difference of the ceil surface expression of these antigens throughout the 
growth cycle, the cultured cells were derived from a donor free of malignancy. 
Several lines of evidence suggest a relationship between malignancy and the ex- 
pression  of  histocompatibility  antigens,  and  qualitative  and  quantitative 
changes of histocompatibility antigens  during  the course of malignancy have 
been documented both in man and mice. H-2 antigens decreased in H-2 homo- 
zygous murine tumor cells (34, 35) and an irreversible loss of antigens controlled 
from one of the two H-2 alleles was observed in H-2 heterozygous tumors (36). 
Furthermore, in TL leukemia cells an inverse relationship existed between the 
quantitative expression of tumor-specific cell surface antigens and normal H-2 
antigens; the phenotypic expression of TL antigens reduced the demonstrable 
amount of certain H-2 antigens on the cell surface (3),  while  the  decrease  of 
TL antigens caused by a modulation phenomenon evoked a compensatory in- 
crease in H-2 antigen expression (38). Parallel observations have been made in 
man; decrease or loss of HL-A antigens have been reported during some malig- 
nancies (39-41), whereas in other cases there has been increased reactivity of 
leukemic cells with some anti-HL-A alloantisera, probabty reflecting heightened 
expression of HL-A antigens (10). Finally, changes in the HL-A profiles of some 
patients with acute leukemia paralleled the activity of the disease as new HL-A 
antigens  appeared during  the  acute phase  of the disease,  disappeared during 
remission, and reappeared during relapse (42). It is pertinent to recall the differ- 
ent effects on the expression of histocompatibility antigens observed on tumor 
cells  and cells derived fl'om a donor free of malignancy after treatment with 
inhibitors of macromolecular synthesis. Actinomycin D, an inhibitor of macro- 
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molecular synthesis, enhanced the cell surface expression of histocompatiblity 
antigens on murine tumor cells (43), but had no detectable effect on cells from a 
nonmalignant donor. I° Still too few data are available to answer the question as 
to  whether  the  malignant process modifies the  regulatory mechanism of the 
synthesis of histocompatibility antigens or only affects their expression on  cell 
surfaces. 
The lack of any detectable quantitative variation of histocompatibility anti- 
gens in cells derived from a donor free of malignancy contrasts with the variable 
expression of other antigens such as blood groups H  (44)  and AB (45)  on cul- 
tured cells. The constancy of histocompatibility antigen expression throughout 
the growth cycle of cultured cells suggests that these cell surface markers are an 
essential part of membrane cytoarchitecture or play a critical role for the normal 
function  of the cell membrane. This view is reinforced by the  persistence  of 
histocompatibility antigens on murine (46)  and human lymphoid cells (47) even 
after long-term culture,  although  other  antigens  are lost  (48,  49).  Similarly, 
human diploid fibroblasts, which have a finite life-span in vitro, change meta- 
bolically, functionally, and morphologically during senescence, but their surface 
expression  of HL-A antigens remains practically unchanged  throughout  their 
in vitro lifetime. 1~' 12 
SUMMARY 
The  interaction  of  histocompatibility  (HL-A)  antibodies  and  complement 
with synchronized human lymphoid cells in continuous culture has been investi- 
gated. The sensitivity of cultured  lymphoid cells to HL-A antibody-mediated 
lysis in the cytotoxic test, the extent of activation of the complement system, 
the degree to which labeled complement components are bound, and the ability 
of these cells to absorb HL-A alloantibodies do not vary significantly during the 
cell  growth  cycle.  The  constancy  of  histocompatibility  antigen  expression 
throughout  the growth  cycle of cultured  cells suggests that  these cell surface 
markers are an essential part of membrane cytoarchitecture and could well play 
a critical role in determining the normal function of the cell membrane. 
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